FDA requires expanded labeling about weight loss risk in patients younger than 6 years for extended‐release stimulants

The FDA is revising the labeling of all extended‐release stimulants indicated to treat attention‐deficit/hyperactivity disorder (ADHD) — including certain formulations of amphetamine and methylphenidate — to warn about the risk of weight loss and other adverse reactions (side effects) in patients younger than 6 years taking these medications.

Publication Details

Journal
The Brown University Child & Adolescent Psychopharmacology Update
Published
2025-08-25
DOI
https://doi.org/10.1002/cpu.31005
Primary Topic
Attention Deficit Hyperactivity Disorder
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FDA requires expanded labeling about weight loss risk in patients younger than 6 years for extended‐release stimulants

The Brown University Child & Adolescent Psychopharmacology Update
Attention Deficit Hyperactivity Disorder
article

FDA requires expanded labeling about weight loss risk in patients younger than 6 years for extended‐release stimulants

article en

Abstract

The FDA is revising the labeling of all extended‐release stimulants indicated to treat attention‐deficit/hyperactivity disorder (ADHD) — including certain formulations of amphetamine and methylphenidate — to warn about the risk of weight loss and other adverse reactions (side effects) in patients younger than 6 years taking these medications.

The Brown University Child & Adolescent Psychopharmacology UpdateVol. 27(9)
Openalex Percentile: Top 74%
Attention Deficit Hyperactivity Disorder
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

FDA requires expanded labeling about weight loss risk in patients younger than 6 years for extended‐release stimulants · The Brown University Child & Adolescent Psychopharmacology Update (2025) | TGRS Research Map | TGRS